A new study reveals carriers of the ApoE4 gene who have chronic inflammation are more likely to develop Alzheimer's disease.
Researchers have identified cognitive subgroups related to genetic differences in Alzheimer's patients. The findings, researchers say, could open the door for more personalized treatments of the neurodegenerative disease.
Researchers have successfully neutralized a genetic risk factor found in up to 80% of Alzheimer's patients. The ability to neutralize ApoE4 could help in the development of a vaccine, as well as other therapeutics, for late onset Alzheimer's.
Post mortem examinations of brain tissue from Alzheimer's patients revealed synapses contained clumps of clusterin, in addition to amyloid beta. The clumps were more abundant in those with genetic risk factors from Alzheimer's disease.
Children with the APOE E4 gene perform lower on verbal and general IQ tests than their peers without the genetic risk factor. APOE E4 is a genetic risk factor for Alzheimer's disease. The study suggests the effects of the gene manifests before adulthood and could be the earliest biomarker for later vulnerability to Alzheimer's disease.
A new blood test for Alzheimer's disease is up-to 94% accurate at predicting dementia before symptoms appear. The test's accuracy is increased when genetic predisposition and age are taken into account. The new test may eventually replace PET neuroimaging, currently considered the gold standard, for early detection of Alzheimer's.
Middle-aged people with the Alzheimer's related APOE4 gene have a harder time accessing recently acquired knowledge, even when they show no symptoms of memory decline.
While being multilingual did not delay the onset of dementia for those at risk, nuns who spoke four or more languages were significantly less likely to develop dementia than those who spoke just one language.
APOE4 increases the inflammatory response of human microglia while reducing cellular migration. The gene also impairs the metabolic activity of the immune cells. The findings show APOE4 has a profound impact on the basic functions of microglia.